U.S. Energy Services Stock News

NasdaqGS:HLIT
NasdaqGS:HLITCommunications

How New Operator Integrations At Harmonic (HLIT) Have Changed Its Investment Story

In February 2026, Harmonic announced new wins and integrations, including Alcom adopting its XOS Advanced Media Processor for Nordic white-label video services, a joint integration with ATX Networks to simplify DOCSIS 4.0 upgrades, and izzi using Harmonic’s cOS virtualized broadband platform to support a large fiber rollout in Mexico. Together, these developments show Harmonic’s technology becoming more deeply embedded in operators’ core broadband and video infrastructures, potentially...
NYSE:CON
NYSE:CONHealthcare

Earnings Beat, Dividend Hike, and Buybacks Might Change The Case For Investing In Concentra (CON)

Concentra Group Holdings Parent, Inc. recently reported its fourth-quarter and full-year 2025 results, with Q4 revenue rising to US$539.08 million and net income to US$34.69 million, while also declaring a US$0.0625 per-share cash dividend payable in March 2026. Management is pairing this earnings momentum with expansion plans focused on smaller, bolt-on acquisitions and a stepped-up de novo clinic pipeline, supported by a new US$100.00 million share repurchase program. We’ll now examine how...
NYSE:UPS
NYSE:UPSLogistics

UPS Network Overhaul Weighs On Costs Valuation And Dividend Coverage

UPS (NYSE:UPS) is accelerating its "Network of the Future" overhaul, which includes closing up to 200 manual package sorting facilities by 2030. The company plans to shift more volume into highly automated hubs as part of a broad redesign of its U.S. operations. UPS is offering employee buyouts and preparing for large-scale workforce reductions as it reconfigures its network. UPS sits at the center of global e‑commerce and business shipping, and its network decisions can influence how...
NYSE:CNH
NYSE:CNHMachinery

Why CNH Industrial (CNH) Is Down 5.8% After Weaker Earnings and a Sharper “Iron + Tech” Pivot

In February 2026, CNH Industrial N.V. reported fourth-quarter 2025 results showing revenue rising to US$5,157 million while quarterly net income fell to US$86 million, and full-year 2025 earnings declined to US$510 million on revenue of US$18,095 million. Despite this earnings pressure, the company’s latest 10-K filing emphasized its “Iron + Tech” approach, prioritizing precision agriculture, automation, and connectivity to reshape its equipment and services model. We’ll now examine how this...
NYSE:AX
NYSE:AXBanks

Why Axos Financial (AX) Is Down 10.8% After Hot PPI Rekindles Fed Rate Cut Doubts

In late February 2026, Axos Financial, a digital-focused US bank, was caught in a broad financial sector downturn after a higher-than-expected January Producer Price Index reading reinforced concerns about persistent inflation and constrained room for near-term Federal Reserve rate cuts. This inflation surprise matters for Axos because sustained elevated rates can pressure bank net interest margins, directly affecting how profitably it turns deposits into loans and other interest-earning...
NYSE:ADC
NYSE:ADCRetail REITs

A Look At Agree Realty (ADC) Valuation After Recent Share Price Momentum And Premium P/E Multiple

Agree Realty (ADC) has drawn attention after its recent share performance, with the stock last closing at $80.48. For income focused investors, the real estate investment trust’s profile may warrant a closer look. See our latest analysis for Agree Realty. The recent 11.8% 1 month share price return, on top of an 11.6% year to date share price return, sits alongside a 5 year total shareholder return of 54.4%, suggesting momentum has been building over both shorter and longer horizons. If this...
NYSE:WD
NYSE:WDDiversified Financial

Walker & Dunlop (WD) Valuation Check As Market Views Clash On Undervaluation And Rich P/E Ratio

Why Walker & Dunlop (WD) is on investors’ radar today Walker & Dunlop (WD) has drawn investor attention after a period of weaker share performance, with the stock showing negative returns over the past year and past 3 months. This has prompted some investors to take a closer look at its fundamentals. At a last close of US$46.01, the company sits against a backdrop of mixed signals. These include a value score of 1 and recently reported annual revenue of US$1,160.01m alongside net income of...
NYSE:SSB
NYSE:SSBBanks

Why SouthState Bank (SSB) Is Down 6.4% After Inflation Jolt Hits Regional Lenders

In late February 2026, SouthState Bank was caught up in a broad financial sector pullback after hotter-than-expected U.S. producer inflation data and renewed concerns about banks’ credit quality and loan performance. The episode underscored how macroeconomic inflation surprises and shifting expectations for Federal Reserve policy can quickly alter sentiment toward regional lenders’ balance-sheet risks. Next, we’ll examine how these inflation and credit-quality concerns interact with...
NasdaqGS:MSFT
NasdaqGS:MSFTSoftware

Is It Time To Reconsider Microsoft (MSFT) After Recent AI And Cloud Growth Focus?

If you are wondering whether Microsoft is still priced attractively or if the best days are already reflected in the share price, this article walks through what the numbers indicate about its current valuation. Microsoft shares last closed at US$392.74, with returns of a 1.1% decline over 7 days, a 9.4% decline over 30 days, a 17.0% decline year to date, a 0.3% decline over 1 year, 57.5% over 3 years and 76.7% over 5 years. This gives you a broad sense of how the stock has behaved across...
NasdaqGM:ANIP
NasdaqGM:ANIPPharmaceuticals

Does Record 2025 Profitability and Reaffirmed 2026 Outlook Change The Bull Case For ANI Pharmaceuticals (ANIP)?

In late February 2026, ANI Pharmaceuticals, Inc. reported past fourth-quarter 2025 sales of US$247.06 million and net income of US$27.49 million, alongside full-year 2025 sales of US$883.37 million and a swing to profitability. The company also reaffirmed its 2026 revenue outlook of US$1.06 billion to US$1.12 billion, underpinned by strong rare disease and generics performance, including expanded uptake of Cortrophin Gel. Now we’ll examine how this record 2025 performance and reaffirmed...
NasdaqGS:PCVX
NasdaqGS:PCVXBiotechs

Vaxcyte (PCVX) Is Up 5.5% After Unveiling VAX-31 Data, Phase 3 Plans And New Financing - Has The Bull Case Changed?

In February 2026, Vaxcyte reported a full-year 2025 net loss of US$766.63 million and higher loss per share, while also raising roughly US$408.10 million through an at-the-market follow-on equity offering and filing additional shelf capacity linked to employee stock plans. Alongside these financing moves, the company highlighted unprecedented Phase 2 results for its VAX-31 pneumococcal vaccine, rapid progression into multiple Phase 3 trials, and completion of a large-scale manufacturing...
NasdaqGS:COLL
NasdaqGS:COLLPharmaceuticals

A Look At Collegium Pharmaceutical (COLL) Valuation After Mixed Q4 2025 Results And Updated 2026 Guidance

Collegium Pharmaceutical (COLL) shares came under pressure after its Q4 and full year 2025 report, where earnings and revenue missed some analyst estimates, while management reaffirmed and slightly lifted 2026 guidance. See our latest analysis for Collegium Pharmaceutical. The Q4 miss has come with a reset in expectations, with the 1 day share price return of a 5.77% decline at US$41.67 extending a 30 day share price return of a 9.26% decline, even though the 1 year total shareholder return...
NYSE:XPOF
NYSE:XPOFHospitality

Assessing Xponential Fitness (XPOF) Valuation After Weak Earnings And Lower 2026 Revenue Guidance

Xponential Fitness (XPOF) is back in focus after reporting fourth quarter and full year 2025 results, along with 2026 revenue guidance that points to a lower range than the prior year. See our latest analysis for Xponential Fitness. The earnings release and lower 2026 revenue guidance have coincided with sharp share price weakness, with a 1 day share price return of 47.08% decline and a 1 year total shareholder return of 67.75% decline. This points to fading momentum and a reassessment of...
NYSE:VMC
NYSE:VMCBasic Materials

Is Vulcan Materials (VMC) Fully Priced After Strong Multi Year Share Price Gains

If you are wondering whether Vulcan Materials is a fair deal at around US$310 per share, it helps to step back and look at what the current price actually reflects. The stock last closed at US$310.00, with returns of 1.5% over 7 days, 3.1% over 30 days, 5.9% year to date, 26.3% over 1 year, 73.4% over 3 years and 92.3% over 5 years, which may shape how investors are thinking about its potential and its risks today. Recent coverage has focused on Vulcan Materials as a key supplier of...
NYSE:MDU
NYSE:MDUGas Utilities

Will Steady Dividends And A US$3.10 Billion Plan Shift MDU Resources Group's (MDU) Narrative

MDU Resources Group’s board recently declared a quarterly dividend of US$0.14 per share, unchanged from the prior quarter, payable on April 1, 2026 to shareholders of record on March 12, 2026, while continuing to target a long-term payout ratio of 60% to 70% of earnings. Alongside reaffirmed earnings guidance and a multi-year US$3.10 billion capital plan as a pure-play regulated utility and pipeline operator, the full exit of activist investor Corvex Management highlights an evolving...
NYSE:AD
NYSE:ADWireless Telecom

How Array’s Tower Pivot And 2026 Revenue Guide At Array Digital Infrastructure (AD) Has Changed Its Investment Story

In February 2026, Array Digital Infrastructure reported fourth-quarter 2025 revenue of US$60.33 million and net income of US$37.48 million, while issuing 2026 revenue guidance of US$200 million to US$215 million as it pivots toward tower and site rental income after selling regional wireless operations and most spectrum licenses. This shift is reshaping the company into a largely tower-focused business, with earnings now more closely tied to long-term lease agreements with major carriers...
NasdaqGM:MIRM
NasdaqGM:MIRMBiotechs

Assessing Mirum Pharmaceuticals (MIRM) Valuation After Recent Share Price Volatility

Mirum Pharmaceuticals stock snapshot after recent performance shifts Mirum Pharmaceuticals (MIRM) has had mixed share-price moves recently, with a small 1 day gain, a 12% decline over the past week, a 10% drop over the past month, and a 32% gain across the past 3 months. Against that backdrop, investors are weighing Mirum’s current US$92.29 share price, its recent return profile over the past year and beyond, and how that lines up with the company’s rare disease portfolio and financial...
NYSE:LB
NYSE:LBReal Estate

LandBridge (LB) Is Up 8.7% After Dividend Hike And New Buyback Plan - What's Changed

In late February 2026, LandBridge Company LLC reported past fourth-quarter revenue of US$56.78 million and net income of US$8.06 million, alongside full-year 2025 revenue of US$199.09 million and net income of US$30.13 million, while also announcing a 20% dividend increase and a new US$50 million share repurchase program. This combination of strong earnings growth, a higher cash dividend, and a sizable buyback authorization underscores management’s confidence in LandBridge’s capital-light...
NYSE:PLNT
NYSE:PLNTHospitality

Why Planet Fitness (PLNT) Is Down 9.4% After Tempered 2026 Guidance Despite Strong 2025 Results

In February 2026, Planet Fitness reported higher Q4 and full-year 2025 revenue and earnings, alongside guidance for 2026 calling for approximately 9% revenue growth. At the same time, the company’s moderated growth outlook and ongoing legal investigations contrasted with continued international expansion, including new franchise-backed clubs in northern Mexico. We’ll now examine how Planet Fitness’s tempered 2026 guidance, despite solid 2025 results, reshapes the company’s longer-term...
NYSE:BK
NYSE:BKCapital Markets

The Bull Case For Bank of New York Mellon (BK) Could Change Following New Series M Preferred Offering

On February 26, 2026, Bank of New York Mellon Corporation priced and completed a US$500,000,000 underwritten public offering of 500,000 Series M Noncumulative Perpetual Preferred Stock depositary shares at US$1,000 each, featuring callable, non-cumulative, variable-rate terms. The planned use of proceeds for general corporate purposes, including potential redemptions of existing Series F and Series H preferred stock, signals a meaningful reshaping of BNY’s capital structure and future...
NasdaqGS:CATY
NasdaqGS:CATYBanks

Cathay General Bancorp (CATY) Is Down 7.1% After Commercial Real Estate Credit Concerns Intensify

In recent days, Cathay General Bancorp has come under pressure as investors reacted to rising credit risk concerns amid hotter-than-expected inflation data and growing worries over regional banks’ exposure to commercial real estate. What makes this episode especially important is that it coincides with Cathay General’s flat sales and declining earnings per share, sharpening questions about its profitability and growth profile. We’ll now examine how heightened credit risk concerns,...
NYSE:SLG
NYSE:SLGOffice REITs

Should SL Green’s Manhattan Leasing Surge and Portfolio Shuffle Require Action From SLG Investors?

SL Green Realty recently reported past leasing gains in Manhattan, signing 56 office leases covering 0.8 million square feet and completing major portfolio moves, including the US$730,000,000 acquisition of Park Avenue Tower and a 49% joint venture sale in 100 Park Avenue, alongside higher average rental rates. An interesting takeaway is how this combination of stronger leasing, higher rents, and active portfolio reshaping is helping offset the earnings pressure created by rising interest...
NasdaqCM:VRDN
NasdaqCM:VRDNBiotechs

Viridian Therapeutics (VRDN) Balances Rising Losses With Veligrotug Milestones and New Employee Stock Shelf Registration

In late February 2026, Viridian Therapeutics reported fourth-quarter and full-year 2025 results showing modest revenue but a larger net loss alongside a new US$16.33 million shelf registration for employee stock offerings. At the same time, the company’s thyroid eye disease program advanced with veligrotug under FDA Priority Review and an EMA filing submitted, reinforcing its focus on late-stage assets despite higher losses. With these regulatory milestones for veligrotug in place, we’ll now...
NYSE:VTOL
NYSE:VTOLEnergy Services

A Look At Bristow Group (VTOL) Valuation After Earnings, 2026 Outlook, Refinancing And New Dividend

Earnings, guidance and capital returns in focus Bristow Group (VTOL) just paired its fourth quarter and full year 2025 results with 2026 guidance, a fresh quarterly dividend and details on a recent US$500 million refinancing at a lower coupon. The company reported Q4 2025 sales of US$377.26 million and net income of US$18.42 million, while affirming 2026 revenue expectations in a US$1.58 billion to US$1.69 billion range and maintaining its new US$0.125 quarterly cash dividend. See our latest...